secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2025-05-05T23:59:59+00:00
Accession:  0001104659-25-044596
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 3.03, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransCode Therapeutics announces 1-for-28 reverse stock split effective May 15, 2025
--------------------------------------------------------------------------------

- Reverse split at 1-for-28 ratio; effective 12:01 a.m. ET on May 15, 2025.
- Outstanding shares reduced from 23,341,336 to approximately 833,620; par value unchanged.
- No fractional shares issued; rounding up to nearest whole share for record holders.
- Split intended to meet Nasdaq minimum bid price requirement; CUSIP changes to 89357L501.
- Stockholder approval obtained May 2, 2025; trading symbol remains RNAZ.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465925044596/0001104659-25-044596-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465925044596/tm2514038d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-044596

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer